contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Nordic Solar is a Danish based operator and developer of solar energy projects. Nordic Solar has a broad geographic spread with projects in more than 12 European countries. Currently, the company has +350 MWp in operations or under construction. The future mid-term growth is supported by a +1750 MWp pipeline and an increasing focus on green energy as the solution to the current European energy crisis.

Nordic Solar targets 2.000 MWp in operations and 4.000 MWp in the pipeline in 2025. The company is not listed on any stock exchange, however, the company has an IPO ambition as part of its financing plan to build out the portfolio.

Husk at læse hele vores research disclaimer på https://www.inderes.dk/disclaimer. Dansk:  Nordic Solar er en dansk operatør og udvikler af solenergiprojekter. Nordic Solar har en bred geografisk spredning med projekter i mere end 12 europæiske lande. I øjeblikket har virksomheden +350 MWp i drift eller under opførelse. Den fremtidige vækst på mellemlang sigt understøttes af en +1750 MWp pipeline og stigende fokus på grøn energi som løsningen på den aktuelle europæiske energikrise. Nordic Solar har et mål om 3.000 MWp i drift og i pipeline i 2025. Selskabet er ikke børsnoteret, men har en IPO ambition som en del af en finansieringsplan for at udbygge porteføljen. English:  Nordic Solar is a Danish-based operator and developer of solar energy projects. Nordic Solar has a broad geographic spread with projects in more than 12 European countries. Currently, the company has +350 MWp in operations or under construction. The future mid-term growth is supported by a +1750 MWp pipeline and an increasing focus on green energy as the solution to the current European energy crisis. Nordic Solar targets 3,000 MWp in operations and in the pipeline in 2025. The company is not listed on any stock exchange, however, the company has an IPO ambition as part of its financing plan to build out the portfolio.

Nordic Solar

Hansa Biopharma is a Swedish biotech company with the lead product imlifidase, which is an antibody-cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients. The enzyme may be further developed for use in other types of transplantation, in autoimmune diseases, gene therapy and oncology. So far Idefirix (imlifidase) has been conditionally approved in the EU for highly sensitized kidney transplant patients.

Currently, Hansa is conducting a pivotal randomized contro trial in kidney transplantation in the United States and is expecting to commence a pivotal study across the U.S. and EU in the rare autoimmune disease anti-GBM during 2022. Additionally, Hansa’s research and development program is advancing the enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology.

Kære forum  Hvis der er nogle af jer som har kendskab til Hansa Biopharma, så meld gerne ind med input  Jeg har selv noget kendskab til Hansa Biopharma og et firma som jeg forventer en god performance af og at de bliver lønsomme fremad og hvis det går som forventede med deres produkt lansering

Husk at læse hele vores research disclaimer på https://www.inderes.dk/disclaimer. Dansk:  Hansa Biopharma er en svensk biotekvirksomhed imlifidase (Idefirix) som hovedproduktet. Imlifidase er et antistof-spaltende enzym, der udvikles til at muliggøre nyretransplantation hos stærkt sensibiliserede patienter. Enzymet kan videreudvikles til brug ved andre typer transplantation, i autoimmune sygdomme, genterapi og onkologi. Hidtil er Idefirix blevet betinget godkendt i EU til højsensibiliserede nyretransplanterede patienter. I øjeblikket udfører Hansa et afgørende randomiseret kontrolforsøg i nyretransplantation i USA og forventer at påbegynde et yderligere afgørende studie på tværs af USA og EU i den sjældne autoimmune sygdom anti-GBM i løbet af 2022. Derudover fremmer Hansas forsknings- og udviklingsprogram enzymteknologien til at udvikle den næste generation af IgG-spaltende enzymer med potentielt lavere immunogenicitet, velegnet til gentagende dosering ved recidiverende autoimmune sygdomme og onkologi. English:  Hansa Biopharma is a Swedish biotech company with the lead product imlifidase, which is an antibody-cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients. The enzyme may be further developed for use in other types of transplantation, in autoimmune diseases, gene therapy and oncology. So far Idefirix (imlifidase) has been conditionally approved in the EU for highly sensitized kidney transplant patients. Currently, Hansa is conducting a pivotal randomized control trial in kidney transplantation in the United States and is expecting to commence a pivotal study across the U.S. and EU in the rare autoimmune disease anti-GBM in 2022. Additionally, Hansa’s research and development program is advancing the enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology.

Hansa Biopharma

Nordic Solar A/S, en unoteret solpark udvikler, fremlagde i sidste uge første kvartalsresultater.
Hansa Biopharma annoncerede her til morgen, at den første patient har modtaget en dosis af selskabets imlifidase i forbindelse med deltagelse i det nye fase 3 studie.

Dagens aktienyheder 30/05: <a class="ql-mention" spellcheck="false" href="https://www.linkedin.com/company/54143576/admin/#" data-entity-urn="urn:li:fsd_company:823969" data-guid="56" data-object-urn="urn:li:organization:823969" data-original-text="Nordic Solar A/S">Nordic Solar A/S</a> og <a class="ql-mention" spellcheck="false" href="https://www.linkedin.com/company/54143576/admin/#" data-entity-urn="urn:li:fsd_company:3081430" data-guid="60" data-object-urn="urn:li:organization:3081430" data-original-text="Hansa Biopharma">Hansa Biopharma</a>
<a class="ql-mention" spellcheck="false" href="https://www.linkedin.com/company/54143576/admin/#" data-entity-urn="urn:li:fsd_company:823969" data-guid="54" data-object-urn="urn:li:fsd_company:823969" data-original-text="Nordic Solar A/S">Nordic Solar A/S</a>, en unoteret solpark udvikler, fremlagde i sidste uge f&oslash;rste kvartalsresultater, hvor f&oslash;rste kvartals resultater var pr&aelig;get af de faldende elpriser, hvilket dog ikke var uventet og de fastholdt ogs&aring; guidance for hel&aring;ret. Lyt med i dag n&aring;r vi sammen med ledelsen l&oslash;ber resultaterne fra starten af &aring;ret igennem og ser ind i resten af 2023. https://www.inderes.dk/videos/nordic-solar-praesentation-af-q1-regnskab-2023
<a class="ql-mention" spellcheck="false" href="https://www.linkedin.com/company/54143576/admin/#" data-entity-urn="urn:li:fsd_company:3081430" data-guid="57" data-object-urn="urn:li:organization:3081430" data-original-text="Hansa Biopharma">Hansa Biopharma</a> annoncerede her til morgen, at den f&oslash;rste patient har modtaget en dosis af selskabets imlifidase i forbindelse med deltagelse i det nye fase 3 studie (GOOP-IDES-02) indenfor den autoimmune sygdom, anti GBM (ogs&aring; kaldet Goopastures Syndrom). I alt 50 patienter skal indg&aring; i fase 3 studiet fordelt p&aring; 30-40 centre i USA og Europa med henblik p&aring; at dokumentere samme gode resultater fra fase 2 studiet, hvor to tredjedele af patienterne ikke beh&oslash;vede at v&aelig;re i dialyse 6 m&aring;neder efter behandling med imlifidase sammenlignet med 18 procent uden behandling. <a class="ql-mention" spellcheck="false" href="https://www.linkedin.com/company/54143576/admin/#" data-entity-urn="urn:li:fsd_company:3081430" data-guid="58" data-object-urn="urn:li:organization:3081430" data-original-text="Hansa Biopharma">Hansa Biopharma</a> deltager i dag p&aring; et deep dive event hos <a class="ql-mention" spellcheck="false" href="https://www.linkedin.com/company/54143576/admin/#" data-entity-urn="urn:li:fsd_company:54143576" data-guid="59" data-object-urn="urn:li:organization:54143576" data-original-text="HC Andersen Capital">HC Andersen Capital</a>, hvor selskabets dykker ned i hvilke andre anvendelsesmuligheder der er med imlifidase. Du kan tilmelde dig her: https://www.inderes.dk/videos/hansa-biopharma-deep-dive-into-other-indications-for-imlifidase
Disclaimer:&nbsp;<a class="ql-mention" spellcheck="false" href="https://www.linkedin.com/company/54143576/admin/#" data-entity-urn="urn:li:fsd_company:54143576" data-guid="55" data-object-urn="urn:li:fsd_company:54143576" data-original-text="HC Andersen Capital">HC Andersen Capital</a>&nbsp;modtager betaling fra selskaberne for en Digital IR aftale.
Jesper Thomsen - 30/05 2023 kl. 09:12